Notice of Proposed Sale · 144
Beta Bionics, Inc.
BBNXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- BETA BIONICS, INC.
- Issuer CIK
- 0001674632
- SEC file number
- 001-42491
- Phone
- 9494277785
- Person for whose account securities are to be sold
- MARK HOPMAN
- Relationships to issuer
- Officer
- Street
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,660 | 50,486.80 | 44,989,688 | 10/01/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2026 | Exercise of Stock Options | Issuer | 2,660 | N | 10/01/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for MARK HOPMAN | Common | 09/16/2026 | 30,779 | 619,641.13 |
| 10b5-1 Sales for MARK HOPMAN | Common | 09/14/2026 | 775 | 12,028.00 |
| 10b5-1 Sales for MARK HOPMAN | Common | 09/09/2026 | 36,870 | 680,723.44 |
| MARK HOPMAN | Common | 09/02/2026 | 5,327 | 101,815.48 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for MARK HOPMAN
- Street
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for MARK HOPMAN
- Street
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Seller — prior-sale row 3, entry 1
- Name
- 10b5-1 Sales for MARK HOPMAN
- Street
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Seller — prior-sale row 4, entry 1
- Name
- MARK HOPMAN
- Street
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ Mark Hopman
- Plan adoption dates
- 06/10/2026
Company context
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. We believe this marks a significant advancement over other insulin delivery technologies by offering a differentiated combination of improved glycemic control an